Sarepta Therapeutics Inc Clinical Update: SRP-9003 for Limb-Girdle Muscular Dystrophy Type 2E Conference Call
Conference Call Sarepta Therapeutics Inc
Sarepta Therapeutics Inc Conference call will be held on Jun 8, 2020. During the earnings conference call's session Sarepta Therapeutics Inc will provide updated information and financial status.
Conference call service enable to conduct an online meeting with several participates at the same time without leaving the room. Earnings call use teleconference platform to conduct an online meeting between the management of a public company, analysts, investors and the media to discuss the financial results during a given reporting period
In order to join the earnings online meeting, contact Sarepta Therapeutics Inc for the information on connecting using web conferencing or bridge number and PIN code
Schedule an online meeting with QCONF conference service and get free conference bridge.
We are a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. Applying our proprietary, highly-differentiated and innovative platform technologies, we are able to target a broad range of diseases and disorders through distinct RNA-targeted mechanisms of action. We are primarily focused on rapidly advancing the development of our potentially disease-modifying DMD drug candidates, including our lead DMD product candidate, eteplirsen, designed to skip exon 51. On August 25, 2015, we announced the FDA filing of our NDA for eteplirsen for the treatment of DMD amenable to exon 51 skipping. The FDA postponed the Advisory Committee meeting for the review of the eteplirsen NDA previously scheduled for January 22, 2016 due to severe weather.Read more Conference Call